BESPONSA safety tracked in over 400 leukemia patients
NCT ID NCT05923112
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the safety of the drug BESPONSA in 421 people with a type of blood cancer called acute lymphocytic leukemia that had come back or stopped responding to treatment. All participants received BESPONSA as prescribed by their doctor. Researchers tracked side effects, especially liver problems, low blood cell counts, infections, and bleeding, for up to a year after starting the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BESPONSA (inotuzumab ozogamicin)
- What this could lead to
- If successful, this study could confirm the safety profile of BESPONSA for treating relapsed or refractory acute lymphocytic leukemia.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove effectiveness. Results may not apply outside Japan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New transplant recipe aims to tame Graft-Versus-Host disease
- Experimental drug RAD001 tested for tough leukemias and lymphomas
- Engineered immune cells take aim at returning blood cancers
- Selective immune cell removal may tame transplant complications
- New hope for tough blood cancers: LP-118 trial launches
- New safety check for Kids' leukemia drug BESPONSA